⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

January 28, 2026SHILAP Revista de lepidopterologíaOpen Access

Role of Intermediate dose escalation of radiotherapy in the survival of unresectable stage III non-small cell lung cancer patients in the era of immunotherapy

Saber A. Amin Chi Lin A. Kishor Ganti W ZHEN Chi Zhang

View Full Paper

Ask AI

Bookmark

Share

Key Points

Survival rates do not significantly improve with intermediate dose escalation of radiotherapy.
Patients receiving immunotherapy more than six weeks post-treatment showed consistent outcomes without dose changes.
Assessment involves analyzing patient survival in relation to radiotherapy and immunotherapy administration timelines.
Findings suggest that dose adjustments may not be necessary, highlighting treatment consistency.

Implication

Observational analysis finds that dose escalation of radiotherapy does not improve survival in lung cancer patients receiving immunotherapy.

Abstract

IDE of RT is not needed for patients diagnosed with stage III unresectable NSCLC who receive immunotherapy > six weeks after dcCRT.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Amin et al. (2026) studied this question.

synapsesocial.com/papers/69a75c2fc6e9836116a24c7a https://doi.org/10.3389/fonc.2025.1652522

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Cancer statistics, 20232023 · 16,240 citations
2Emerging Therapies for Stage III Non-Small Cell Lung Cancer: Stereotactic Body Radiation Therapy and ImmunotherapyHuman Clinical Trial · 2017 · 26 citations
3Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapyRetrospective Study · 2018 · 28 citations
4Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410Cohort Study · 2011 · 1,233 citations
5Therapeutic management options for stage III non-small cell lung cancerReview · 2017 · 243 citations

Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer2010
A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the radiation therapy oncology group1980
Primary Analysis of the Phase II Component of a Phase I/II Dose Intensification Study Using Three-Dimensional Conformal Radiation Therapy and Concurrent Chemotherapy for Patients With Inoperable Non–Small-Cell Lung Cancer: RTOG 01172010
Catalogue of the Castniidae in the National Museum of Ireland - Natural History, Dublin, with general comments on the history of the collection (Insecta: Lepidoptera)SHILAP Revista de lepidopterología · 2026
Integrative Taxonomic Characterization and first DNA Barcoding of Chrysozephyrus syla (Kollar, [1844]) and C. birupa (Moore, 1877) for Indian species (Lepidoptera: Lycaenidae)SHILAP Revista de lepidopterología · 2026

More from SHILAP Revista de lepidopterología

More from Mayo Clinic in Arizona

More from University of Nebraska Medical Center

More from Susan Thompson Buffett Foundation